Lesaffre Expands its Focus on Nutrition and Health with the Acquisition of NattoPharma

Lesaffre announced the completion of its take-over of NattoPharma, a Norwegian nutraceutical company specializing in research and marketing of vitamin K2. With this acquisition, Gnosis by Lesaffre, the business unit of Lesaffre dedicated to human care, is strengthening its presence in the global human nutrition and health market and confirms its commitment to accelerate its research and development activities.

This announcement completes the friendly public offer launched in February to acquire all outstanding shares of NattoPharma, a company listed on Euronext Expand Oslo. Given that Lesaffre now holds more than 90% of the share capital of NattoPharma, a delisting and compulsory acquisition of the remaining shares will be carried out in due course.

With the acquisition of NattoPharma, a company headquartered in Norway and specializing in vitamin K2, Lesaffre confirms its commitment to becoming a key player in this double-digit-growth market. Through its business unit Gnosis by Lesaffre, Lesaffre is already an established supplier of Vitamin K2, an ingredient used in dietary supplements, with benefits in bone health and cardiovascular health. Joining forces with NattoPharma will help Gnosis by Lesaffre expand the awareness about and access to the benefits of Vitamin K2 to support the health capital of consumers.

“This acquisition is perfectly in line with our strategy of development in human nutrition and health. We are very happy to welcome the NattoPharma team within our group. Lesaffre and NattoPharma share a common goal of answering the needs for food, health and naturalness while providing safe and trustworthy ingredients to their clients and end customers”, says Antoine Baule, CEO of Lesaffre.